A carregar...

Biosimilar Insulins – What a Clinician Needs to Know?

As the first biologics produced by recombinant deoxyribonucleic acid (DNA) technology were approved in the late 1980s and consequently the exclusive marketing rights of most of these biological medicinal products have expired or will expire very shortly, it is quite evident that biosimilars are bein...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Indian J Endocrinol Metab
Main Authors: Ghosh, Sujoy, Bose, Saptarshi, Gowda, Sandeep, Mukhopadhyay, Pradip
Formato: Artigo
Idioma:Inglês
Publicado em: Wolters Kluwer - Medknow 2019
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6844176/
https://ncbi.nlm.nih.gov/pubmed/31741896
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/ijem.IJEM_180_19
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!